Weber Barbara 4

What Happened
Barbara Weber, a director of Parabilis Medicines (PBLS), received a derivative equity award on 2026-06-09 covering 20,215 shares. The filing reports the acquisition price as $0.00 (no cash paid at grant) and the reported value at grant is $0. This grant is a compensatory/derivative award (not an open-market purchase or sale).

Key Details

• Transaction date: 2026-06-09; Form 4 filed: 2026-06-11 (timely).
• Instrument: Derivative award (option/award) for 20,215 shares; reported acquisition price $0.00.
• Vesting/exercise: Footnote states the shares underlying the option vest and become exercisable in full upon the earlier of (i) June 9, 2027 or (ii) the issuer’s next annual meeting, subject to continued service.
• Shares owned after transaction: not specified in the provided summary of the filing.
• Filing status: Appears timely (filed within the required reporting window).

Context
This was a compensatory equity grant to a board director — common as part of director pay. It does not represent an immediate open-market purchase or sale and does not realize value until vesting/exercise and any subsequent sale. The ultimate value to the insider depends on the award’s exercise price and Parabilis’s future stock price; the filing treats this as a derivative award with vesting tied to continued service.